ADMA
ADMA Biologics Inc
9.40$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +46.8% | -112.6% | – | -45.2% | +100.6% | -139.2% | – | -37.1% | +168.1% | +63.4% | -49.3% | – | |
| – | -25.0% | +0.2% | +7.6% | -14.7% | +0.2% | +1.3% | +4.5% | -1.7% | +1.1% | -10.1% | -3.2% | – | |
| – | +3.0% | +22.7% | +33.7% | +11.0% | +70.9% | -14.9% | +7.3% | +1.7% | +6.8% | +17.4% | -3.1% | – | |
| – | -7.0% | -780.8% | – | -256.9% | – | -513.5% | – | – | – | – | -235.8% | – | |
| – | +58.2% | +96.0% | -12.0% | -48.9% | +161.1% | +70.5% | -48.5% | +493.2% | -92.5% | +134.6% | -11.3% | – | |
| – | +85.9% | +67.8% | +0.1% | -53.6% | +150.5% | +71.6% | -46.5% | +468.6% | -98.1% | – | -193.8% | – | |
| – | +63.7% | +627.3% | -72.0% | – | -120.3% | +1,022.4% | -100.0% | – | -61.4% | +1,362.5% | -80.8% | – | |
| – | – | – | – | – | +0.0% | -100.0% | – | – | +0.0% | – | -100.4% | – | |
| – | -9,473.5% | -96.3% | -75.0% | +6,935.1% | +21.8% | -77.0% | – | -58,068.8% | -67.2% | +11.1% | +190.4% | – | |
| – | -295.8% | – | – | -103.6% | – | -291.7% | – | -254.9% | – | +92.5% | -104.2% | – | |
| – | +46.1% | -127.8% | – | -45.0% | +98.0% | -151.4% | – | -105.7% | – | +61.2% | -51.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.